TP53 and neoplasm: Pathologic deregulation of IGF1R gene expression as a result of tumor-specific, loss-of-function p53 mutations may lead to increased cell-surface IGF1R concentrations and enhanced IGF1R phosphorylation by locally produced and/or endocrine IGF1 and IGF2.